Meeting
2019 ASCO Annual Meeting
NMR-metabolite-resonance signature to predict HR+ breast cancer patient response to CDK4/6 inhibitors.
Authors
Bo Zhang
Olaris Therapeutics, Cambridge, MA
Bo Zhang , Jason Warner , Christopher Pinto , Dejan Juric , Elizabeth ODay
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3043)
DOI
10.1200/JCO.2019.37.15_suppl.3043
Abstract #
3043
Poster Bd #
35
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression.
First Author: Laura Sabina Lapuchesky
Poster
2019 ASCO Annual Meeting
Lasofoxifene as a potential treatment for ER+ metastatic breast cancer.
First Author: Muriel Laine
Poster
2023 ASCO Annual Meeting
Discovery of CDK4/6 bifunctional degraders for ER+/HER2- breast cancer.
First Author: Hannah Majeski
Poster
2023 ASCO Annual Meeting
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
First Author: Manish R. Patel